ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.

ABSTRACT: In chronic lymphocytic leukemia (CLL), analysis of TP53 aberrations (deletion and/or mutation) is a crucial part of treatment decision-making algorithms. Technological and treatment advances have resulted in the need for an update of the last recommendations for TP53 analysis in CLL, published by ERIC, the European Research Initiative on CLL, in 2018. Based on the current knowledge of the relevance of low-burden TP53-mutated clones, a specific variant allele frequency (VAF) cut-off for reporting TP53 mutations is no longer recommended, but instead, the need for thorough method validation by the reporting laboratory is emphasized. The result of TP53 analyses should always be interpreted within the context of available laboratory and clinical information, treatment indication, and therapeuti

SUBMITTER: Malcikova J 

PROVIDER: S-EPMC11217004 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature